Company intelligence / Profile preview

Genosaber

Shanghai, Shanghai, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

Genosaber specializes in the development and promotion of comprehensive liquid biopsy solutions, primarily for genetic profiling and monitoring of cancers such as lung cancer. The company is active in precision medicine, with a focus on minimally invasive diagnostics using circulating biomarkers. There are no reported clinical trial results for therapeutic products; the company's offerings are diagnostic platforms rather than drugs or biologics.

Therapeutic areas: Oncology
Modalities: Liquid biopsy technology (platform)
Industry: Molecular Diagnostics

Drug pipeline

1 asset

CytoploRare

Commercial

Indications: Non-small cell lung cancer

Partnerships

Participated in Chinese Lung Cancer Summit expert panels with academic and industry partners

Beyond the preview

Go deeper on Genosaber.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genosaber.

Explore the full profile